Patrick Faloon Email & Phone Number

Cambridge, Ma, Us

Cambridge, Massachusetts, Us

Established state-of-the-art drug discovery team to enable our Discovery Biology & Computational Biology group's pursuit of novel disease targets. This effort encompasses assay technologies (e.g., high content imaging, mass spectrometry & biochemical approaches), automation, compound management and identifying components to generate an integrated software environment. In addition to managing internal efforts, I am working with several CROs to complement internal capabilities.

Cambridge, Ma, Us

• Established HTS & Compound Management Platforms:Designed, outfitted and staffed a state-of-the-art HTS platform to support target-based and phenotypic small molecule drug discovery. Facilitated application of induced pluripotent stem cell (iPSC)-based assays for multiple projects. Identified and implemented data analysis tools to support HTS & assay efforts. Sourced external CROs for screening and compound management. Planned and designed new laboratories for two lab relocations.• Pipeline Planning & Management: Managed exploratory project pipeline as part of departmental management team. Represented BHTS in multiple cross-disciplinary committees including a phenotypic working group and a chemogenomics team. Provided training opportunities to colleagues in other departments to facilitate application of HTS-related technologies via an open access lab. Established an antisense oligonucleotide (ASO) working group to coordinate efforts and research tools across the drug discovery organization.• Team Leadership: Managed an internal HTS facility (schedule, maintenance, staffing & improvements) managing multiple discovery projects per year with a team of 1 Ph.D. Scientist & 3 senior associate scientists to support small molecule discovery, whole genome CRISPR screening and gene therapy-associated studies.• Research and Development Project Leader (RDPL): Design, drive and coordinate efforts across Research & Development for two small molecule phenotypic drug discovery projects in Hit Identification stage, including project advancement from exploratory phase onward, asset strategy, presentation to governance boards, budgeting, including the management of collaborations with an external company and an academic lab for one project.

Cambridge, Ma, Us

•Established HTS & Compound Management Platforms:Designed, outfitted and staffed a state of the art HTS platform to support small molecule drug discovery, both ‘walk-up’ instrumentation and fully automated robotic systems. Identified and implemented software tools to support HTS efforts. Sourced external CROs for screening and compound management and managed CRO relationships. Establish and build capabilities for phenotypic screening programs including use of primary cells, endogenous assay readouts and iPSCs.•Pipeline Planning & Management: Managed exploratory project pipeline as part of departmental management team. Reviewed and prioritized screening projects based upon feasibility and relevance criteria. Planned and coordinated internal HTS projects, as well as, with CROs. Interacted with colleagues in Therapeutic Areas to facilitate creation of new projects and assays. •Team Leadership: Managed a high throughput screening (HTS) facility (schedule, infrastructure maintenance, staffing & improvements) executing multiple HTS projects per year while overseeing a team of 3 associates. Appointed as Research and Development Project Leader (RDPL) to drive a program from the exploratory phase onward which requires planning, experimental design, and coordinating across multiple functions to support research, medicinal chemistry, Lead ID, Lead Optimization and supproting actvities for Research to Development transition.

Cambridge, Ma, Us

• Scientific Collaborations: Led 2 drug discovery collaborations with Bayer Healthcare Corporation-Oncology. Collaborated with external academic groups as part of the NIH’s NIH Molecular Libraries Probe Production Centers Network (MLPCN).• Pipeline planning & Management: Managed discovery project pipeline as part of departmental management team. • Team Leadership: Managed a high throughput screening (HTS) facility (schedule, infrastructure maintenance, staffing & improvements) executing >20 HTS projects per year including a team of 2 Ph.D. scientists, 6 associates and 3 automation engineers. Annually mentored summer students as part of the Broad Institute’s education program.• Pre-clinical HTS & Assay Development: Developed & optimized high throughput cell-based & biochemical assays. Coordinated & managed medicinal chemists during lead optimization studies. Wrote and published 10 peer-reviewed MLPCN probe reports on small molecule probes to the NIH.• Community Education & Outreach: Promoted group capabilities to regional scientific leaders to initiate collaborations and educate academic researchers about small molecule discovery. Provided facility tours to prospective external partners, political leaders, faculty, teachers, and student groups.

Cambridge, Ma, Us

Manage and implement large scale small molecule screens using both cell-based and biochemical assays. We perform projects as part of the NIH's Molecular Probes (MLPCN) program which involves developing assays in collaboration with academic researchers, analysis of large data sets and pursuit of medicinal chemistry.

• Clinical Candidate Drug Repurposing: Performed suite of cell-based assays to identify new biological activities for mature compounds provided by external partners. Designed & implemented new cell-based assays.

Basel, Baselstadt, Ch

Created zebrafish model of neuroinflammation. and performed small molecule screens to inhibit neurotoxicity and dampen the response of microglia. Secondary activities included: creation of cell-specific reporter transgenic lines, collaborating on ENU-based mutagenesis screens and establishing the NIBR postdoctoral association.

Boston, Ma, Us

• Functional Genomics: Initiated a phenotypic genetic screen for vascular and developmental deficiencies and characterized vasculogenesis defects in zebrafish genetic mutants. Positionally cloned zebrafish rhogef7, a GTPase that is critical for vascular integrity.• Animal Model Development: Constructed a genomic “knock-in” construct and genetically modified murine embryonic stem cells for the establishment of a mouse line.

Boston, Ma, Us

I had a dual appointment at MGH and HMS for this fellowship. I positionally cloned a zebrafish signaling protein important for vascular development and assisted in defining lysocardiolipin acyltransferase in embryonic stem cell development.

St. Louis, Mo, Us

• Phenotypic Characterization of Developmental Progenitors: Determined the limitations of in vitro derived Flk-1+ cells contributing to in vivo hematopoietic and endothelial populations. Proved a role for the receptor tyrosine kinase, flk1/vegfr2, the transcription factor, SCL/TAL1 and the receptor, Fgfr2 in hematopoietic and vascular progenitor development using in vitro differentiation of embryonic stem cells.• Biomarker Screening: Generated hybridomas & created a panel of monoclonal antibodies to generate new biomarkers for the hemangioblast and endothelial cells.• Functional Assays: Characterization of a cell immortalization phenomena resulting from retroviral insertion into the CDT1 locus using cell cycle flow cytometry and tumor formation assays in rag2-/- mice.• Leadership: Trained research technicians & postdoctoral fellows. Managed the relocation, setup and organization of the laboratory.

Ph.D., Molecular And Cell Biology

Molecular And Cell Biology

Bachelor Of Science (B.S.), Marine Sciences